Technical Pulse on Pharma Stocks -- Research on Pfizer, Hospira, Endo Intl., and Nektar Therapeutics

Editor Note: For more information about this release, please scroll to bottom.

LONDON, July 7, 2014 /PRNewswire/ --

The US markets on Thursday, July 3, 2014 ended on a positive note as the Dow Jones Industrial Average finished at 17,068.26, up 0.54% and the NASDAQ Composite closed at 4,485.93, up 0.63%. The S&P 500 finished the session 0.55% higher at 1,985.44. During the trading session, nine out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 721.38, up 0.41%, with the index gaining 7.38% in the previous three months. Investor-Edge has initiated coverage on the following equities: Pfizer Inc. (NYSE: PFE), Hospira Inc. (NYSE: HSP), Endo International PLC (NASDAQ: ENDP) and Nektar Therapeutics (NASDAQ: NKTR). Free technical research on PFE, HSP, ENDP and NKTR can be downloaded upon signing up at:

On Thursday, Pfizer Inc.'s stock fluctuated between $30.29 and $30.64 before ending the session 0.53% higher at $30.53. The stock reported a trading volume of 14.85 million shares, below its three months average volume of 29.04 million shares. Shares of the company traded at a PE ratio of 13.07. Pfizer Inc.'s shares have advanced 2.86% in the previous three trading sessions and 3.77% in the last one month, while the stock has fallen by 0.33% on YTD basis. The stock is trading above its 50-day moving averages of $29.77, which is below Pfizer Inc.'s 200-day moving average of $30.61. Moreover, Pfizer Inc.'s stock has a Relative Strength Index (RSI) of 65.43. Sign up today to read free research on PFE at:

On Thursday, Hospira Inc.'s stock edged 0.28% lower, to close the day at $52.49. The stock recorded a trading volume of 0.31 million shares, below its three months average volume of 1.10 million shares. The company shares oscillated between $52.18 and $52.88 during the session. Over the last one month and over the past three months, Hospira Inc.'s shares have advanced 3.37% and 21.00%, respectively. Further, the stock has gained an upside of 27.16% since the start of this year. The stock is trading above its 50-day and 200-day moving averages. Hospira Inc.'s 50-day moving average of $49.07 is above its 200-day moving average of $43.51. Additionally, the stock traded at a PE ratio of 30.18 and has an RSI of 64.20. Sign up today to read free research on HSP at:

On Thursday, shares in Endo International PLC recorded a trading volume of 0.87 million shares, lower than its three months average volume of 2.72 million shares. The stock ended the day at $69.26, which was 0.32% below its previous day's closing of $69.48, and registered an intraday range of $69.02 and $70.19. Shares of the company traded at a PE ratio of 106.42. Although Endo International PLC's stock has fallen by 1.09% in the previous three trading sessions, it has advanced 0.26% in the last one month and 2.67% on YTD basis. The company's stock is trading above its 50-day and 200-day moving averages of $68.86 and $64.01, respectively. Furthermore, shares of Endo International PLC have an RSI of 48.91. Sign up today to read free research on ENDP at:

Nektar Therapeutics' stock finished the Thursday's session 0.15% lower at $13.25. A total of 0.45 million shares were traded, which was below its three months average volume of 1.19 million shares. The stock vacillated between $13.07 and $13.34 during the session. Over the last one month and over the previous three months, Nektar Therapeutics' shares have surged 18.41% and 19.26%, respectively. Additionally, from the beginning of 2014, the company's stock has gained 16.74%. The company's shares are trading above their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $12.02 is greater than its 200-day moving average of $11.98. Nektar Therapeutics' stock has an RSI of 57.81. Sign up today to read free research on NKTR at:


1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at]

5. For any urgent concerns or inquiries, please contact us at compliance [at]

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] for consideration.

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge

Suggested Articles

Former Indivior CEO Shaun Thaxter will face six months in federal prison for his role in misleading government officials on the dangers of Suboxone.

As of Friday after local time, 36 people have died in Korea after getting flu shots provided by at least seven companies, including Sanofi.

Two prominent pneumococcal vaccines from Merck and Pfizer are running low in Europe in a possible ill omen for the coming winter: report.